Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
Explore More Articles
Laser scleral microporation: Unique method to treat presbyopia goes back to basics
Laser scleral microporation is a unique therapeutic solution for presbyopia that goes back to basics, rejuvenating the eye and restoring the natural dynamic mechanism of accommodation and disaccommodation. “Nature frequently develops dynamic processes, which work well for most individuals for the first 40 or 50 years of life but then, because of changes in the intrinsic …
read moreA New Paradigm Shift: Parts 1 and 2 (Pages 25-31)
DUE TO THE AGING OF THE population, most of our population will spend roughly half of their lives as presby-opes. The etiology of presby-opia has been poorly understood, and treatment options have failed to address the true issues with the disease, creating compro mises in vision that patients are eager to find a solution for, …
read moreLaser scleral microporation helps turn back the clock for presbyopic eyes
VIENNA — In this Healio Video Perspective from the ESCRS meeting, Robert Ang, MD, shares his results with laser scleral microporation for the treatment of presbyopia. He explains the rationale of laser scleral microporation (Ace Vision Group), how it is performed, and the advantages of a treatment that does not interfere with the visual axis and allows the …
read more